In another study, miR-619-5p and miR-4486 were both down-regulated in serum from eosinophilic ACO patients versus either COPD or asthma, while both miRNAs participate in two common pathways, metabolism of xenobiotics by cytochrome P450 and ErbB signalings, suggesting that targeting the EGFR signaling pathway or NRF2 modulators could be used as a novel therapeutic approach for ACO [77]. Here, EGFR is linked to asthma.